Personalised Cancer Plan

Stop Guessing. Start Targeting

Because your cancer is as unique as your DNA, your treatment should be too.

Precision insights that complement standard oncology care to guide next-step planning and ongoing monitoring.

Why do I need this test if I already have a diagnosis?

Standard oncology often treats cancer based on where it started (the organ). But two people with lung cancer can have completely different biological drivers. Without a Personalised Cancer Plan, you are essentially fighting an invisible enemy. Our testing removes the blindfold, allowing your medical team to see exactly which ‘locks’ your cancer uses, so we can find the right ‘key’ to stop it.

What is Personalised Cancer Care

A Personalised Cancer Plan combines standard mainstream treatments with precision medicine to guide intelligent and individualized treatments.

In a published study, researchers observed encouraging results for patients receiving precision oncology compared with standard care.

In a published study comparing matched vs non-matched approaches:1,2

  • Median overall survival: 11.4 vs 8.6 months
  • Time without progression: 4.0 vs 2.8 months
  • Tumor response observed in 27% vs 5% of patients
  • Disease control reported in 70% vs 27%

Matching treatment to a patient’s cancer profile may be associated with more favorable outcomes.

Smarter Insight. Clearer Direction.
1. Results observed in a published study. Individual outcomes may vary.
2. Source: Tsimberidou et al., 2014, Journal of Clinical Oncology (MD Anderson IMPACT precision oncology program). This research is based on 1,144 patients with advanced cancer treated within the MD Anderson IMPACT precision oncology program, comparing matched targeted therapy with non-matched approaches.

Median overall survival (Months)1,2

0
5
10
15
8.6
months
11.4
months
Non-matched
therapy
VS
Matched
therapy

Median progression-free survival (months)1,2

0
2
4
6
2.8
months
4
months
Non-matched
therapy
VS
Matched
therapy
1. Results observed in a published study. Individual outcomes may vary.
2. Source: Tsimberidou et al., 2014, Journal of Clinical Oncology (MD Anderson IMPACT precision oncology program). This research is based on 1,144 patients with advanced cancer treated within the MD Anderson IMPACT precision oncology program, comparing matched targeted therapy with non-matched approaches.
A Personalised Cancer Plan combines standard care with precision medicine to guide smarter, more individualised treatment decisions.
In advanced cancer cases, precision approaches have demonstrated meaningful clinical impact:
  • Overall survival improved from 25.8 to 51.7 weeks
  • Progression-free survival increased from 12.0 to 22.9 weeks
  • Late-stage survival extended from approximately 6 months to over 15 months
  • Disease control achieved in 41% of patients
Smarter Insight. Clearer Direction.
Clinical outcomes (Advanced cancer)

Impact of Precision Oncology

Median Overall Survival (OS)
Weeks
Standard care
25.8
Precision oncology
51.7
~2× longer median OS
Statistically significant (P = 0.008)
Progression-Free Survival (PFS)
Weeks
Standard care
12.0
Precision oncology
22.9
Improved median PFS
Statistically significant (P = 0.002)
Note: Values shown as median survival in weeks for advanced cancer patients.
Personalised Cancer Plan

Supporting clearer, more informed treatment decisions

For cancer patients, caregivers, and clinicians

Cancer treatment involves many important decisions guided by clinical evaluation, imaging, pathology, and established medical guidelines.

Advances in precision medicine allow doctors to understand cancer at a biological level, adding insight that may support treatment planning and monitoring.

Integrates standard medical care with biological information
Supports more personalised, condition-appropriate decisions
Helps clarify options for discussion with your oncology team
Disclaimer: This information is for educational purposes and does not replace professional medical advice.

To the family member searching for answers tonight..
Contact our Professional Team for Liquid Biopsy

What is your benefit?

To support improved treatment outcomes by helping identify treatments that may be more effective for your specific cancer — while helping minimise unnecessary side effects from less effective treatments.

Treatment Choice Can Significantly Impact Survival
In late-stage cancer cases, targeted precision approaches have shown substantial improvement in overall survival.
Conventional / Non-targeted approach
~6 months
Average survival in difficult late-stage cases.
With targeted precision treatment
15+ months
Extended survival observed in selected patients using targeted therapy.

A Personalised Cancer Plan

🧫
Circulating tumour cells
(CTCs) analysis
🧬
Circulating tumour DNA
(ctDNA) profiling
🧾
Genomic or molecular testing
🔬
Biomarker analysis
📊
Clinical research evaluation
Precision Medicine in Lung Cancer
Molecular profiling improves detection and survival outcomes in selected lung cancer patients.
+30%
Increase in Early Diagnosis
Improved early detection in lung cancer.
Up to 21 Months
Extended OS & PFS
Observed in rare mutation cases receiving targeted therapy.
The Hidden Risk of “Standard” Treatment
Two patients may share the same diagnosis — yet respond completely differently to the same therapy.
Without understanding the biological profile of the tumour, treatment decisions rely only on population averages.
And averages do not treat individuals.
Precision medicine helps reduce uncertainty by revealing how your specific cancer behaves — before critical time is lost.
When Facing Cancer, Information Is Power
The earlier you understand your cancer’s biology, the better your treatment decisions can be guided.
Speak to Our Precision Oncology Team
Advanced cancers — Key outcomes
Works alongside standard cancer care to support more informed treatment planning.
Disease Control Rate (DCR)
41.2%
95% CI: 24.7%–59.3%
Median PFS
2.7 months
Progression-free survival
Median OS
9.9 months
Overall survival
Note: Values shown with 95% confidence interval where applicable.
References
Selected clinical studies supporting the use of precision medicine in oncology.
No. Study Title Year Key Findings (Simplified) Clinical Relevance
1
Longer survival with precision medicine in late-stage cancer patients
View study
2025 Targeted therapy group lived 15.7 months vs 5–6 months without targeted selection; 44% showed meaningful benefit. Suggests improved survival in selected late-stage cases when treatment is biologically matched.
2
Benefits of precision medicine in lung cancer: experience from a single institution
View study
2022 Early detection improved by 30%; rare mutation patients achieved up to 21 months OS/PFS with specific targeted drugs. Demonstrates the value of molecular profiling in improving early diagnosis and treatment selection.
3
Impact of Precision Medicine on Clinical Outcomes: A Single-Institution Retrospective Study
View study
2021 23% tumour shrinkage; 41% disease control rate; average overall survival approximately 10 months. Indicates enhanced disease control when treatment decisions incorporate additional biological data.
4
Precision oncology in advanced cancer improves overall survival with lower weekly healthcare costs
View study
2018 Overall survival 52 weeks vs 26 weeks; progression-free survival 23 vs 12 weeks. Suggests survival benefit and potential cost efficiency in selected advanced cancer populations.
5
Retrospective analysis of precision medicine outcomes in advanced cancer patients
View study
2016 Progression-free survival 23 vs 12 weeks without increased healthcare costs. Shows improved time without disease worsening when therapy is guided by tumour profiling.
For educational purposes only. Clinical outcomes vary depending on tumour biology, stage, patient condition, and treatment context.

Contact our Professional Team for Liquid Biopsy

What is your benefit?

To support improved treatment outcomes by helping identify treatments that may be more effective for your specific cancer — while helping minimise unnecessary side effects from less effective treatments.

Contact Us

Contact Us for the updated information on Precision Medicine

Call / Whatsapp Us

+852 4750 3485

Email Us

info@mycancerinfo.org

Send Us a Message